Effects of a Rheumatoid Arthritis Self-management Program: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Effects of a Rheumatoid Arthritis Self-management Program (NCT03470740), a randomized na study. The primary outcome is Disease Activity.

2. Clinical Question

The clinical question is about a group-level difference in a continuous score at the stated follow-up, not about how every participant changed or responded. The registry describes the trial as randomized, single-masked, and parallel. It also states that the program’s aims included assessing effectiveness with 6 months of follow-up and understanding intervention participants’ experiences. The registry record does not provide a qualitative result about those experiences, nor does it clarify who was masked. The principal statistical comparison available is the unadjusted difference in mean disease activity, interpreted alongside its interval and the limitations of the posted record.

3. Trial Design

The registry identifies this study as a randomized, single-masked, parallel-group trial of a behavioral intervention. It is marked completed. Enrollment is recorded as 224, and the two posted groups each have 112 participants in the primary outcome summary. The record gives a start date of 2016-09-01 and a primary completion date of 2018-07-31.

The intervention group received an individualized rheumatoid arthritis self-management program. The description links the program to self-efficacy theory and says it addressed physical behavioral problems, with emphasis on knowledge and skill. The control group received general information on rheumatoid arthritis care and follow-up. The registry does not report the exact allocation procedure, whether allocation was concealed, or which people involved in the trial were masked. It also does not report enough detail to assess the delivery, adherence, or fidelity of the intervention.

The primary outcome was disease activity at 6 months. The registry lists secondary outcomes related to arthritis self-efficacy, quality of life, physical functioning, and self-management behaviors. While the record lists these outcomes, a complete set of corresponding results and analyses is not reported in the registry record. The stated study aims also included understanding intervention participants’ experiences, but qualitative findings are not reported in the registry record.

The registry record does not report the original sample-size justification, the planned statistical analysis, interim analyses, or the analysis population. Those omissions limit assessment of how closely the posted results follow the original protocol. Randomization supports a comparison between assigned groups in principle, but interpretation still depends on the details of implementation, follow-up, missing data, and analysis—many of which are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Disease Activity, measured over 6 months.

The primary endpoint is disease activity at 6 months, measured with the DAS-28 (Disease Activity Score-28). The record describes this measure as evaluating 28 tender and swollen joint counts in people with rheumatoid arthritis. Scores can range from 0 to 9.4, with lower scores representing a better rheumatoid arthritis outcome. The posted result is a mean and standard deviation for each group.

DAS-28 is used as a continuous measure that condenses information about joint tenderness and swelling into a score, allowing average disease activity to be compared between randomized groups. A group mean describes the central level of the measured score; the standard deviation describes variation among the scores around that mean. Neither statistic shows the full distribution or the experience of each individual participant.

The registry record does not report additional details about how the measure was collected, who assessed it, or whether other components contributed to the calculation. The endpoint is a measure of disease activity, not a direct measure of self-management skills, quality of life, or participants’ experience of the program. Those topics appear elsewhere among the stated aims or secondary outcomes, but they are not interchangeable with the primary measure.

7. Results Posted in the Registry

• Intervention Group: mean 3.38 versus 3.62 on control; difference -0.24 (95% CI -0.56 to 0.08), standardized effect d = -0.20; z-test p = 0.137.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Arthritis Self-efficacy- Pain

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Intervention Group: mean 35.21 versus 32.72 on control; difference 2.49 (95% CI -0.15 to 5.13), standardized effect d = 0.25; z-test p = 0.064.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Intervention Group and the control. The interval gives the range of effects that remain compatible with the data.

Arthritis Self-efficacy- Other

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Intervention Group: mean 51.71 versus 48.96 on control; difference 2.75 (95% CI -0.01 to 5.51), standardized effect d = 0.26; z-test p = 0.051.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Intervention Group and the control. The interval gives the range of effects that remain compatible with the data.

SF-36 Quality of life_Physical Component Scores

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Intervention Group: mean 51.29 versus 48.88 on control; difference 2.41 (95% CI -0.08 to 4.90), standardized effect d = 0.25; z-test p = 0.058.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Intervention Group and the control. The interval gives the range of effects that remain compatible with the data.

The registry lists secondary outcomes spanning arthritis self-efficacy, quality of life, physical functioning, and self-management behaviors. The available numeric secondary summaries include arthritis self-efficacy for pain and other symptoms, and the SF-36 physical component score. For these reported comparisons, the intervention-group means are higher than the control-group means. Their unadjusted intervals include zero or come very close to it, so the summaries leave uncertainty about the corresponding group differences.

This broad directional pattern does not overturn or independently confirm the primary disease-activity result. The primary outcome measures disease activity, whereas the secondary measures address different constructs. A pattern in self-efficacy or quality-of-life scores cannot be substituted for evidence about disease activity, and a primary result cannot be assumed to describe all secondary domains. The registry record does not report a complete analysis for every listed secondary outcome, so a full cross-outcome synthesis is not possible.

Secondary comparisons carry less weight when they are unadjusted and when a plan for handling multiple outcomes is not reported. General statistical explanation: examining many outcomes creates more opportunities for an apparently notable finding to arise by chance. A prespecified multiplicity strategy can help control the interpretation of that family of comparisons. The registry record does not report such a strategy or identify which secondary outcomes, if any, were designated as confirmatory.

For these reasons, the secondary results are best treated as exploratory context around the primary comparison. They may identify domains for further study, but they do not establish a consistent benefit across outcomes or demonstrate a mechanism for any difference in disease activity. The registry record does not provide enough analysis detail to determine whether all measured secondary outcomes, time points, or analysis choices are represented in the posted results.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Arthritis Self-efficacy- Pain
• Arthritis Self-efficacy- Other
• SF-36 Quality of life_Physical Component Scores
• Physical Functioning
• Self-management Behaviors
• SF-36 Quality of Life_Mental Component Scores (MCS)

9. Statistical Interpretation

10. Statistical Methods Explained

The primary result is a comparison of means for a continuous outcome. The intervention group’s mean disease activity score is 3.38, with a standard deviation of 1.15; the control group’s mean is 3.62, with a standard deviation of 1.26. A mean difference expresses the contrast between these group averages. In the posted comparison, the direction is intervention minus control, giving -0.24. The negative sign indicates that the intervention-group mean is lower on this scale; the scale description says lower scores represent a better rheumatoid arthritis outcome.

What does the standard deviation describe?

General statistical explanation: a standard deviation describes how dispersed individual measurements are around a group mean. It is not the uncertainty in the mean itself, and it is not an interval for the treatment contrast. A larger standard deviation indicates greater spread in the observed scores. The standard deviations show that individual scores vary within both groups, so the difference between group means must be interpreted against that variability.

What does the interval around a mean difference tell us?

General statistical explanation: a confidence interval represents a range of effect estimates compatible with the data and the calculation’s assumptions at a stated confidence level. A narrower interval indicates greater precision; a wider interval indicates more uncertainty. The registry record does not identify the confidence level for the posted comparison interval. The interval for the primary mean difference is -0.556 to 0.076. It includes zero, which means the data do not clearly distinguish the observed contrast from no mean difference under this calculation. Inclusion of zero does not prove equivalence or rule out potentially relevant differences.

How should the p-value be read?

The unadjusted p-value for the primary comparison is 0.137. General statistical explanation: a p-value describes how unusual data at least as discrepant as those observed would be under a specified null model and its assumptions. It is not the probability that the null hypothesis is true, nor does it measure the size or importance of an effect. Here, the p-value is an unadjusted result based on the posted group summaries; it should not be read as a complete analysis of the trial.

The registry record does not report a sponsor analysis, a planned model, covariate adjustment, or the statistical test used for its own analysis. The posted mean difference and p-value are therefore best interpreted as unadjusted summary-based comparisons, not as evidence that every prespecified analytic choice has been reproduced. The record marks the discrepancy indicator as false, so there is no flagged disagreement between the posted summary-based result and a reported sponsor estimate. However, a sponsor analysis is not separately described in the registry record.

Why can variation affect the comparison?

General statistical explanation: a mean difference is estimated with uncertainty that depends on the amount of information and the variability of the measurements. With more variation, a given contrast can be harder to estimate precisely. Standard errors quantify uncertainty in an estimated statistic under a particular method; they are distinct from standard deviations, which describe variation among observations. The summary includes group standard errors, but the registry record does not explain an analysis model that uses them.

General statistical explanation: over-dispersion matters when data vary more than a model expects. In that setting, standard errors can be too small if the model does not account for the extra variability, making intervals too narrow and tests too optimistic. The primary endpoint is reported as a continuous score with group means and standard deviations. The registry record does not report an over-dispersion assessment or a model-based analysis, so such an issue cannot be evaluated from the available information.

General statistical explanation: randomization is intended to make assigned groups comparable on average, while masking can reduce some forms of bias in care or assessment. The registry identifies randomized allocation and single masking, but does not describe who was masked, how assignment was implemented, or whether outcome assessment could be influenced by knowledge of group. These design labels are useful, but they do not replace details on trial conduct.

The registry record also does not report baseline disease activity, change from baseline, missing-data handling, analysis populations, or a multiplicity plan. These omissions matter because they determine how to interpret the comparison, how robust it is to incomplete follow-up, and how to account for examining several outcomes. The available statistical interpretation should therefore remain focused on the posted group summaries and their unadjusted contrast.

11. Confidence Intervals and Precision

The primary mean difference is -0.24, with an interval from -0.556 to 0.076. This interval spans zero and includes both negative and positive values. It therefore leaves uncertainty about the direction and size of the underlying mean contrast: the data are compatible with a lower mean in the intervention group, little or no difference, and a higher mean. The interval’s upper endpoint is close to zero, but the interval as a whole does not establish that the groups are equivalent.

The estimate is a point summary, not a precise description of every participant’s outcome. The group standard deviations are 1.15 and 1.26, while the mean difference is smaller in magnitude than either standard deviation. This context indicates substantial variation in individual scores relative to the observed contrast, though it does not by itself determine clinical importance. The registry record does not report a threshold for a clinically important difference, so the clinical meaning of the numerical contrast cannot be judged from this comparison alone.

The registry does not state the confidence level for the interval, and it does not provide a confidence interval from a described sponsor analysis. The interval should therefore be understood as the posted comparison interval, without assigning an unreported confidence level or model. The unadjusted p-value of 0.137 is consistent with the uncertainty conveyed by the interval, but it does not replace the interval or quantify the probability that the result is true.

Precision also depends on completeness of follow-up and analysis choices. Missing outcome information, the analysis population, and any adjustment for baseline values are not reported in the registry record. Those unknowns limit how fully the interval can represent uncertainty in the trial’s intended analysis.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are participants per arm, not total events. They are illustrations computed from the observed effect, using a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each row considers detecting the stated fraction of the observed effect. These are planning assumptions for the illustration; the trial’s own original sample-size assumptions are not reported in the registry record.

The 80% power column gives the planned participants per arm for a hypothetical study to have an 80% chance of detecting the specified effect under the stated assumptions, if that effect and the model assumptions were correct. The 90% power column describes the corresponding hypothetical planning target with a higher chance of detecting that effect. These are design calculations, not guarantees about the outcome of a future study. The illustrations are not observed power.

The row for 100% of the observed effect uses the effect estimated in this trial as the target for planning. Rows for 75% and 50% of the observed effect use smaller target effects. Smaller effects are harder to distinguish from sampling variation, so they require more participants per arm under the same assumptions. The displayed figures can help show how sensitive planning is to the effect size chosen, but they should not be mistaken for the number actually enrolled or for evidence that the trial was designed around its observed result.

The registry record does not report the trial’s original sample-size rationale, target effect, or power calculation. The planning illustrations cannot fill that gap, because they are recalculated from the observed effect rather than recovered from the original protocol. They are most useful for understanding the scale of a hypothetical study under the stated assumptions, not for judging the adequacy of the completed trial.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -0.240; pooled standard deviation σ = 1.206.
2. n = 2 × (1.96 + 0.842)² × 1.206² / -0.240² = 396.5, rounded up to 397 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -0.24                      # observed difference in means
sigma <- 1.20625453367024                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(3470740)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 397 (80% power), 531 (90% power)
 75% of observed effect: n per arm = 705 (80% power), 944 (90% power)
 50% of observed effect: n per arm = 1,587 (80% power), 2,124 (90% power)
power.t.test: 397.5 
Simulated power at n = 397 per arm: 0.797 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry record lists multiple secondary outcomes in addition to the primary disease-activity endpoint. It does not report a multiplicity adjustment, a hierarchy for testing outcomes, or an indication of which secondary comparisons were intended to be confirmatory. When several outcomes are examined, unadjusted p-values and intervals do not account for the number of comparisons. General statistical explanation: without a planned approach to multiplicity, apparently favorable results among many outcomes may be less persuasive because chance findings become more likely across a collection of tests. The posted secondary comparisons should therefore be interpreted cautiously.

Missing-data handling is not reported in the registry record. The primary outcome summaries show 112 participants in each group, but the record does not explain whether these are all randomized participants, participants with observed outcomes, or another analysis population. It does not report the amount or pattern of missing outcome data, reasons for missingness, or any imputation or sensitivity analysis. Consequently, it is not possible to assess whether incomplete follow-up could have affected the group comparison.

The record also does not specify an intention-to-treat population, a per-protocol population, or another analysis set. It does not report how protocol deviations, adherence, or participants who did not receive the assigned intervention were handled. These details matter because an analysis based on assigned groups answers a different question from one restricted to participants who completed or adhered to treatment.

The registry record does not report a detailed statistical analysis plan, baseline-adjusted estimates, interim analyses, or the exact method used for the posted comparison. The absence of these details is not evidence that such procedures were not used; it means they are not reported in the registry record. Together, the omissions limit assessment of selective reporting, robustness to missingness, and alignment between the posted summaries and the trial’s planned analysis.

15. What the Result Does, and Does Not, Mean

The posted result describes a lower average disease-activity score in the intervention group than in the control group at 6 months. The estimated unadjusted mean difference is -0.24, and the interval extends from -0.556 to 0.076. Since lower DAS-28 scores represent a better rheumatoid arthritis outcome, the estimate’s direction is consistent with a lower average score in the intervention group. The interval nevertheless includes zero, so the result does not clearly establish a difference between group means.

This is a finding about the measured group averages, not a guarantee about an individual’s outcome. The result does not show how much any particular person’s score changed, whether the intervention altered disease activity over time, or whether every participant experienced the same direction of change. Baseline disease-activity results and individual-level changes are not reported in the registry record.

The result also does not establish that the intervention has no effect. An interval that includes zero reflects uncertainty; it can include a range of possible differences. Nor does the result prove equivalence, because an equivalence margin and a suitable equivalence analysis are not reported in the registry record. Clinical importance cannot be determined from the numerical estimate alone because a clinically important difference threshold is not reported.

The trial examined a self-management program and included outcomes beyond disease activity, but the primary endpoint is not a direct measure of every aspect of self-management or quality of life. Secondary findings have their own uncertainty and are not reported with a stated multiplicity strategy. The registry record also lacks key information about missing data, analysis populations, intervention adherence, and the original analysis plan.

Accordingly, the posted statistics support a cautious description of the observed comparison, not a broad conclusion about all possible effects, settings, or follow-up periods. They do not amount to medical advice. Further interpretation requires the complete trial report and fuller information about methods and results, which are not reported in the registry record.

16. Why This Trial Matters Statistically

This trial is statistically instructive because its randomized, parallel-group design is paired with a continuous primary outcome and an unadjusted comparison of group means. The direction of the observed difference and its uncertainty can be considered together: the intervention-group mean is lower, but the interval includes zero. This illustrates why a point estimate alone is not enough to assess the strength or precision of a finding.

The trial also highlights the distinction between statistical evidence and clinical interpretation. The DAS-28 scale’s direction is stated, but the registry record does not report a threshold for a clinically important difference. A result can be described statistically without claiming that its size is clinically meaningful. Similarly, a non-significant unadjusted comparison does not establish no effect or equivalence.

The secondary outcomes show why a broader outcome set requires careful interpretation. Outcomes about self-efficacy, quality of life, physical functioning, and behavior address different questions. Without a reported multiplicity plan, individual unadjusted comparisons have limited confirmatory weight. The trial therefore provides a useful example of why a primary endpoint, secondary endpoints, and the analysis plan must be distinguished.

Finally, the registry record leaves important analytical details unreported, including missing-data handling, analysis populations, and the original sample-size rationale. Planning illustrations based on an observed effect can communicate how target effects relate to study size, but they cannot reconstruct the trial’s design assumptions. Transparent reporting of these methods is essential for judging how much confidence to place in a posted estimate and how it could inform future research.

17. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to the information available for this trial. The description of the intervention is incomplete in the registry record: it identifies an individualized self-management program and its self-efficacy basis, but does not fully describe its content, dose, delivery, or implementation. The control condition is described as general care information and follow-up, without further detail. This makes it difficult to assess how distinct the groups’ experiences were.

Although the trial is marked single-masked, the registry record does not identify who was masked or explain how masking was maintained. It also does not describe allocation concealment, the sequence-generation procedure, or baseline characteristics. These reporting gaps prevent a detailed appraisal of potential sources of bias and group comparability.

The primary result is reported at 6 months, but baseline disease activity, change from baseline, and other follow-up results are not reported in the registry record. The record does not describe missing outcomes, adherence, protocol deviations, analysis populations, or sensitivity analyses. These omissions restrict interpretation of the estimate and its applicability to all randomized participants.

The registry lists additional outcome domains, but a complete set of results and analyses is not reported in the registry record. Nor is a multiplicity plan or original statistical analysis plan described. Adverse-event entries for both groups are recorded as zero, but the record also shows zero participants at risk for those entries. These entries do not establish that no adverse events occurred or provide a meaningful comparison of safety.

Finally, the registry record does not report a clinically important difference threshold or the trial’s original sample-size justification. The planning illustrations based on the observed estimate cannot address whether the original design was adequately powered for its intended question.

18. Related Tutorials

19. Related Statistical Calculators

20. Sources

• ClinicalTrials.gov: Effects of a Rheumatoid Arthritis Self-management Program — NCT03470740.
• Registry record last updated 2025-08-22; status last verified 2018-03.
• Results first posted 2019-08-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

21. Record Summary

The registry record describes a completed randomized, single-masked, parallel-group trial of an individualized rheumatoid arthritis self-management program versus general rheumatoid arthritis care information and follow-up. Enrollment is recorded as 224. The primary outcome was DAS-28 disease activity at 6 months, with lower scores representing a better rheumatoid arthritis outcome.

The posted mean scores were 3.38 for the intervention group and 3.62 for the control group. The unadjusted mean difference was -0.24, with an interval from -0.556 to 0.076 and an unadjusted p-value of 0.137. The interval includes zero, leaving uncertainty about the size and direction of the group difference.

The registry lists secondary outcomes, but does not report a complete analysis plan, multiplicity strategy, missing-data handling, or analysis populations. Planning figures are illustrations based on the observed effect, not the trial’s original design assumptions.